Revitalizing equine metabolism: how SHBG improves mitochondrial function and reduces inflammation.
Authors: Bourebaba Nabila, Domagała Justyna, Bourebaba Lynda
Journal: BMC veterinary research
Summary
# Editorial Summary Sex hormone-binding globulin (SHBG) has emerged as a potential therapeutic target for metabolic dysfunction in equines, particularly given the condition's inflammatory underpinnings and mitochondrial dysfunction. Researchers exposed equine cells to 50 nM SHBG and evaluated changes in cellular viability, mitochondrial dynamics and bioenergetics, alongside inflammatory markers, using gene expression analysis to characterise mechanistic pathways. Treatment substantially improved mitochondrial flexibility through upregulation of key fusion and mitophagy genes (MFN-1, PARKIN, PINK1), whilst simultaneously enhancing expression of genes governing mitochondrial protein synthesis and oxidative phosphorylation capacity—suggesting enhanced energy production and metabolic resilience. Notably, SHBG dampened the inflammatory cascade characteristic of equine metabolic syndrome (EMS) by suppressing pro-inflammatory IL-1β and IL-6 whilst promoting anti-inflammatory IL-10 and IL-13 expression. These findings suggest SHBG warrants investigation as a nutraceutical or therapeutic intervention in managing metabolic and inflammatory complications in horses, though in vivo efficacy, optimal dosing strategies, and effects on performance and clinical outcomes require further evaluation before clinical adoption.
Read the full abstract on PubMed
Practical Takeaways
- •SHBG shows promise as a potential therapeutic target for equine metabolic syndrome, though this is preliminary in vitro work requiring in vivo validation before clinical application
- •The dual mechanism of improving mitochondrial efficiency and reducing systemic inflammation could address two key pathological features of EMS
- •Further research with animal models and clinical trials is needed before recommending SHBG-based interventions in practice
Key Findings
- •SHBG treatment at 50 nM significantly upregulated mitochondrial dynamics genes (MFN-1, PARKIN, PINK) indicating enhanced mitochondrial flexibility
- •SHBG improved mitochondrial oxidative phosphorylation (OXPHOS) system function through upregulation of mitoribosomes and related genes
- •SHBG markedly reduced EMS-induced inflammation by decreasing pro-inflammatory cytokines IL-1β and IL-6 while increasing anti-inflammatory IL-10 and IL-13 expression